Publications by authors named "Rachel Midgley"

Claim this Profile
M
Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer.
Andrew D Beggs, Mark P Dilworth, Enric Domingo, Rachel Midgley, David Kerr

Oncoscience· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.
Maryam A Hamdollah Zadeh, Elianna M Amin, Coralie Hoareau-Aveilla, Enric Domingo, Kirsty E Symonds, Rachel S Midgley

Mol Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Dan Rosmarin, Claire Palles, David Church, Enric Domingo, Angela Jones, Rachel Midgley

J Clin Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
Enric Domingo, David N Church, Oliver Sieber, Rajarajan Ramamoorthy, Yoko Yanagisawa, Rachel Midgley

J Clin Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Joanne Brady, Pippa Corrie, Ian Chau, Raghunadharao Digumarti, Laurel M Adams, Rachel S Midgley

Invest New Drugs· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGF-β: an emerging player in drug resistance.
Diede Brunen, Stefan M Willems, Udo Kellner, Rachel Midgley, Iris Simon

Cell Cycle· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers in early-stage colorectal cancer: ready for prime time?
David Church, Rachel Midgley, David Kerr

Dig Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stage II colon cancer.
David N Church, Rachel Midgley, David J Kerr

Chin Clin Oncol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
Gary K Schwartz, Richard D Carvajal, Rachel Midgley, Scott J Rodig, Paul K Stockman

Invest New Drugs· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought.
Rachel S Midgley, David J Kerr

J Clin Oncol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
Enric Domingo, Rajarajan Ramamoorthy, Dahmane Oukrif, Daniel Rosmarin, Michal Presz, Rachel Midgley

J Pathol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer.
Jérémie H Lefevre, Carolina Bonilla, Chrystelle Colas, Bruce Winney, Elaine Johnstone, Rachel Midgley

J Hum Genet· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.
Andrew D Beggs, Enric Domingo, Megan McGregor, Mikael Presz, Elaine Johnstone, Rachel Midgley

Oncotarget· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.
Malcolm G Dunlop, Sara E Dobbins, Susan Mary Farrington, Angela M Jones, Claire Palles, Rachel Midgley

Nat Genet· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The emergence of 'omics for the management of colorectal cancer.
Rachel S Midgley, David Church, David J Kerr

Curr Opin Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Jeanne Tie, Lara Lipton, Jayesh Desai, Peter Gibbs, Robert N Jorissen, Rachel Midgley

Clin Cancer Res· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients.
Carolina Bonilla, Jérémie H Lefèvre, Bruce Winney, Elaine Johnstone, Susan Tonks, Rachel Midgley

J Hum Genet· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33.
Richard S Houlston, Jeremy Cheadle, Sara E Dobbins, Albert Tenesa, Angela M Jones, Rachel Midgley

Nat Genet· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Rachel S Midgley, Christopher C McConkey, Elaine C Johnstone, Janet A Dunn, Justine L Smith

J Clin Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?
Yoko Yanagisawa, Rachel S Midgley

Nat Rev Clin Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene profiling in early stage disease.
Rachel Midgley, Kakil Rasul, Haitham Al Salama, David J Kerr

Cancer J· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can we treat cancer for a dollar a day? Guidelines for low-income countries.
David J Kerr, Rachel Midgley

N Engl J Med· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?
David J Kerr, Rachel Midgley

J Clin Oncol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quinone oxidoreductase-2-mediated prodrug cancer therapy.
Mark R Middleton, Richard Knox, Emma Cattell, Udo Oppermann, Rachel Midgley

Sci Transl Med· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver.
Thinn P Pwint, Rachel Midgley, David J Kerr

Semin Oncol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis